You need to temper your excitement and remember to differentiate a personal opinion on a drug versus whether trial endpoints were actually met in an acceptable manner to the regulator. In this case allowing CHMP to recommend its approval to the EMA.
Just as we can't use the overall conflated EMA approval stats to claim the chance of approval based on the Anavex P2b/3 trial, one can't cite a single drug we don't like passing clock stop 1 as clear indication of a a pass for pet stock drug.
Market Data 
Markets 
